Cytek Biosciences (CTKB) Enterprise Value (2020 - 2026)

Cytek Biosciences has reported Enterprise Value for 7 years, with the latest figure at -$65.7 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 31.06% year-over-year to -$65.7 million; the trailing twelve-month figure through Mar 2026 stood at -$65.7 million (up 31.06% YoY), and the FY2025 full-year result was -$90.9 million, up 7.99% from the prior year.
• Enterprise Value for Q1 2026 stood at -$65.7 million, up from -$90.9 million in the prior quarter.
• The five-year high for Enterprise Value was -$65.7 million in Q1 2026, with the low at -$349.9 million in Q2 2022.
• Historically, Enterprise Value has averaged -$174.1 million across 5 years, with a median of -$162.3 million in 2024.
• Annual changes were most pronounced in 2022 — Enterprise Value plunged 118.9% — and 2023, when it surged 62.41%.
• Cytek Biosciences' Enterprise Value stood at -$299.5 million in 2022, then jumped by 44.03% to -$167.6 million in 2023, then soared by 41.09% to -$98.7 million in 2024, then gained by 7.99% to -$90.9 million in 2025, then rose by 27.69% to -$65.7 million in 2026.
• The last three Enterprise Value figures came in at -$65.7 million (Q1 2026), -$90.9 million (Q4 2025), and -$93.3 million (Q3 2025), per Business Quant data.